Antimicrobial de-escalation in cancer patients

Infection

Volumn 40, Issue 2, 2012, Pages 223-224

  Rolston, K V I ^a   Mahajan, S N ^a   Chemaly, R F ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLYCOSIDE; ANTIINFECTIVE AGENT; CARBAPENEM; CEFEPIME; CEFTAZIDIME; COTRIMOXAZOLE; ERTAPENEM; IMIPENEM; MEROPENEM; PIPERACILLIN PLUS TAZOBACTAM; QUINOLONE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC SENSITIVITY; ANTIMICROBIAL THERAPY; ASPIRATION PNEUMONIA; BACTEREMIA; CANCER PATIENT; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG RESPONSE; FEVER; HEMATOLOGIC MALIGNANCY; HIGH RISK PATIENT; HUMAN; IMMUNOCOMPROMISED PATIENT; INFECTION; INFECTION RISK; LETTER; NEUTROPENIA; NEUTROPENIC ENTEROCOLITIS; NONHUMAN; PATIENT MONITORING; PNEUMONIA; RISK FACTOR; STRATEGIC PLANNING; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; WOUND INFECTION;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CRITICAL CARE; FEMALE; GRAM-POSITIVE BACTERIAL INFECTIONS; HUMANS; IMMUNOCOMPROMISED HOST; MALE;

EID: 84863198310     PISSN: 03008126     EISSN: 14390973     Source Type: Journal    
DOI: 10.1007/s15010-011-0221-6     Document Type: Letter

References (7)

1. Shime N, Satake S, Fujita N. De-escalation of antimicrobials in the treatment of bacteraemia due to antibiotic-sensitive pathogens in immunocompetent patients. Infection. 2011;39:319-25.
2. Dellit TH, Owens RC, McGowan JE, et al. Infectious diseases of America and the society for healthcare epidemiology of American guidelines for developing an institutional program to enhance antimicrobial stewardship. Clin Infect Dis. 2007;44:159-77. (Pubitemid 46084814)
3. Freifeld AG, Bow EJ, Sepkowitz KA, et al. Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 update by the infectious diseases society of America. Clin Infect Dis. 2011;52:e56-93.
4. Ohmagari N, Hanna H, Graviss L, et al. Risk factors for infections with multidrug-resistant Pseudomonas aeruginosa in patients with cancer. Cancer. 2005;104:205-12. (Pubitemid 40847770)
5. Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV. Incidence of fluoroquinolone-resistant and extended-spectrum b-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy. 2011;57:335-8.
6. Rolston KVI. Challenges in the treatment of infections caused by Gram-positive and Gram-negative bacteria in patients with cancer and neutropenia. Clin Infect Dis. 2005;40:S246-52. (Pubitemid 40411206)
7. Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1-12.